Watch for Resmetirom to Treat NASH

July 2024

Resmetirom (Rezdiffra) will be the first med approved for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis in adults.

About 5% of adults in the US have NASH.

You will start to hear NASH called metabolic dysfunction-associated steatohepatitis (MASH)...to reflect its link with cardiometabolic risk factors (diabetes, dyslipidemia, obesity, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Obesity & Weight Loss Provide Answers About GLP-1 Agonists for Weight Loss
Dermatology Identify Med Culprits of Dermatologic Emergencies
Education and Training Help Learners and Colleagues Conquer Impostor Syndrome
Liver Disease Watch for Resmetirom to Treat NASH
Ophthalmology Navigate Options for Acute Conjunctivitis
Infectious Diseases Stay Alert for Rising Rates of Bacterial Meningitis
Appropriate Med Use Watch for Deprescribing Opportunities
NatMed Spotlight Be Ready for Questions About Shilajit

Watch for Resmetirom to Treat NASH

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents